Literature DB >> 23072565

Statistical tools for dose individualization of mycophenolic acid and tacrolimus co-administered during the first month after renal transplantation.

Flora T Musuamba1, Michel Mourad, Vincent Haufroid, Martine De Meyer, Arnaud Capron, Isabelle K Delattre, Roger K Verbeeck, Pierre Wallemacq.   

Abstract

AIM: To predict simultaneously the area under the concentration-time curve during one dosing interval [AUC(0,12 h)] for mycophenolic acid (MPA) and tacrolimus (TAC), when concomitantly used during the first month after transplantation, based on common blood samples.
METHODS: Data were from two different sources, real patient pharmacokinetic (PK) profiles from 65 renal transplant recipients and 9000 PK profiles simulated from previously published models on MPA or TAC in the first month after transplantation. Multiple linear regression (MLR) and Bayesian estimation using optimal samples were performed to predict MPA and TAC AUC(0,12 h) based on two concentrations.
RESULTS: The following models were retained: AUC(0,12 h) = 16.5 + 4.9 × C1.5 + 6.7 × C3.5 (r(2) = 0.82, rRMSE = 9%, with simulations and r(2) = 0.66, rRMSE = 24%, with observed data) and AUC(0,12 h) = 24.3 + 5.9 × C1.5 + 12.2 × C3.5 (r(2) = 0.94, rRMSE = 12.3%, with simulations r(2) = 0.74, rRMSE = 15%, with observed data) for MPA and TAC, respectively. In addition, bayesian estimators were developed including parameter values from final models and values of concentrations at 1.5 and 3.5 h after dose. Good agreement was found between predicted and reference AUC(0,12 h) values: r(2) = 0.90, rRMSE = 13% and r(2) = 0.97, rRMSE = 5% with simulations for MPA and TAC, respectively and r(2) = 0.75, rRMSE = 11% and r(2) = 0.83, rRMSE = 7% with observed data for MPA and TAC, respectively.
CONCLUSION: Statistical tools were developed for simultaneous MPA and TAC therapeutic drug monitoring. They can be incorporated in computer programs for patient dose individualization.
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23072565      PMCID: PMC3635598          DOI: 10.1111/bcp.12007

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

1.  Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods.

Authors:  Aurélie Prémaud; Yannick Le Meur; Jean Debord; Jean-Christophe Szelag; Annick Rousseau; Guillaume Hoizey; Olivier Toupance; Pierre Marquet
Journal:  Ther Drug Monit       Date:  2005-06       Impact factor: 3.681

2.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

3.  Measurement of tacrolimus (FK506) and its metabolites: a review of assay development and application in therapeutic drug monitoring and pharmacokinetic studies.

Authors:  A M Alak
Journal:  Ther Drug Monit       Date:  1997-06       Impact factor: 3.681

4.  Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation.

Authors:  Christine E Staatz; Stephen B Duffull; Bryce Kiberd; Albert D Fraser; Susan E Tett
Journal:  Eur J Clin Pharmacol       Date:  2005-07-28       Impact factor: 2.953

5.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

6.  Some suggestions for measuring predictive performance.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

7.  Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.

Authors:  Serge Cremers; Rik Schoemaker; Eduard Scholten; Jan den Hartigh; Jacqueline König-Quartel; Eric van Kan; Leendert Paul; Johan de Fijter
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

Review 8.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation.

Authors:  M D Hale; A J Nicholls; R E Bullingham; R Hené; A Hoitsma; J P Squifflet; W Weimar; Y Vanrenterghem; F J Van de Woude; G A Verpooten
Journal:  Clin Pharmacol Ther       Date:  1998-12       Impact factor: 6.875

10.  Population pharmacokinetics of tacrolimus in adult kidney transplant recipients.

Authors:  Christine E Staatz; Charlene Willis; Paul J Taylor; Susan E Tett
Journal:  Clin Pharmacol Ther       Date:  2002-12       Impact factor: 6.875

View more
  8 in total

1.  Predictive Performance of Published Tacrolimus Population Pharmacokinetic Models in Thai Kidney Transplant Patients.

Authors:  Janthima Methaneethorn; Manupat Lohitnavy; Kamonwan Onlamai; Nattawut Leelakanok
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-11-24       Impact factor: 2.441

Review 2.  Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?

Authors:  Emily Brooks; Susan E Tett; Nicole M Isbel; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

3.  Toward a robust tool for pharmacokinetic-based personalization of treatment with tacrolimus in solid organ transplantation: A model-based meta-analysis approach.

Authors:  Tom M Nanga; Thao T P Doan; Pierre Marquet; Flora T Musuamba
Journal:  Br J Clin Pharmacol       Date:  2019-12-17       Impact factor: 4.335

4.  Predicting tacrolimus concentrations in children receiving a heart transplant using a population pharmacokinetic model.

Authors:  Joseph E Rower; Chris Stockmann; Matthew W Linakis; Shaun S Kumar; Xiaoxi Liu; E Kent Korgenski; Catherine M T Sherwin; Kimberly M Molina
Journal:  BMJ Paediatr Open       Date:  2017-11-22

5.  Early prognostic performance of miR155-5p monitoring for the risk of rejection: Logistic regression with a population pharmacokinetic approach in adult kidney transplant patients.

Authors:  Luis Quintairos; Helena Colom; Olga Millán; Virginia Fortuna; Cristina Espinosa; Lluis Guirado; Klemens Budde; Claudia Sommerer; Ana Lizana; Yolanda López-Púa; Mercè Brunet
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

6.  A Systematic Review of Multiple Linear Regression-Based Limited Sampling Strategies for Mycophenolic Acid Area Under the Concentration-Time Curve Estimation.

Authors:  Joanna Sobiak; Matylda Resztak
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-09-04       Impact factor: 2.441

7.  Predicting model-informed precision dosing: A test-case in tacrolimus dose adaptation for kidney transplant recipients.

Authors:  Ruben Faelens; Nicolas Luyckx; Dirk Kuypers; Thomas Bouillon; Pieter Annaert
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-02-02

8.  The impact of omeprazole on mycophenolate pharmacokinetics in kidney transplant recipients.

Authors:  Mohamed S AbdElhalim; Ahmed S Kenawy; Heba H El Demellawy; Amany A Azouz; Sarah S Alghanem; Torki Al-Otaibi; Osama Gheith; Mohamed Abd ElMonem; Mohammed K Afifi; Raghda R S Hussein
Journal:  Kidney Res Clin Pract       Date:  2020-12-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.